This study reveals a high level of behavioral heterogeneity in engineered T cells that target tumor organoids. Behavior-guided transcriptomics identified the gene signatures of T cells with highly potent serial cytotoxicity. Integration of the organoid and T cell transcriptomic data enabled the design of patient-specific combinatorial treatment to achieve an optimized response to cancer immunotherapies.
Your institute does not have access to this article
Access options
Subscribe to Nature+
Get immediate online access to the entire Nature family of 50+ journals
$29.99
monthly
Subscribe to Journal
Get full journal access for 1 year
$99.00
only $8.25 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.
References
Chen, D. S. & Mellman, I. Elements of cancer immunity and the cancer-immune set point. Nature 541, 321–330 (2017). A report on the limitations of immunotherapy for solid tumors.
Hegde, P. S. & Chen, D. S. Top 10 challenges in cancer immunotherapy. Immunity 52, 17–35 (2019). A Perspective article that presents the current challenges in optimization of cancer immunotherapy.
Tuveson, D. & Clevers, H. Cancer modeling meets human organoid technology. Science 364, 952–955 (2019). A Review discussing the use of organoids as tumor models that recapitulate the original tumor characteristics.
Ganesh, K. et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat. Med. 25, 1607–1614 (2019). A research article showing the potential of organoids for personalized treatment.
Crainiciuc, G. et al. Behavioural immune landscapes of inflammation. Nature 601, 415–421 (2022). A research article that demonstrates how behavioral profiling can be used to infer immune cell function.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Dekkers, J. F. et al. Uncovering the mode of action of engineered T cells in patient cancer organoids. Nat. Biotechnol. https://doi.org/10.1038/s41587-022-01397-w (2022).
Rights and permissions
About this article
Cite this article
BEHAV3D: an imaging and transcriptomics platform that unravels T cell antitumor activity. Nat Biotechnol (2022). https://doi.org/10.1038/s41587-022-01398-9
Published:
DOI: https://doi.org/10.1038/s41587-022-01398-9
